A Multicenter, Open Label Cohort Phase 1 Dose Finding Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 Mesylate for Oral Administration in Adult Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML), Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
Latest Information Update: 02 Feb 2022
At a glance
- Drugs PF 114 (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- Sponsors Fusion Pharmaceuticals
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 13 Feb 2020 Planned End Date changed from 1 Apr 2019 to 1 May 2020.
- 13 Feb 2020 Status changed from recruiting to active, no longer recruiting.